COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
08/03/2019
BOSTON, March 08, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic [...]
Tauriga Sciences Inc. to Produce Additional Tauri-Gum™ Inventory Due to Stronger than Expected Indications of Demand
08/03/2019
New York, NY, March 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]
Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019
08/03/2019
REHOVOT, Israel and BRIDGEWATER, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and [...]
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
08/03/2019
WATERTOWN, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on [...]
Rexahn Pharmaceuticals Reports 2018 Financial Results
08/03/2019
ROCKVILLE, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers [...]
electroCore Appointments Multiple Industry Veterans to Key Management Positions
08/03/2019
Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer BASKING RIDGE, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic [...]
Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
08/03/2019
Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019 Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-501 and Use of ALLO-647 for Lymphodepletion in Patients with Relapsed/Refractory [...]
AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena® (hydroxyprogesterone caproate injection)
08/03/2019
WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today topline results from PROLONG (Progestin’s Role in Optimizing Neonatal Gestation), a randomized, double-blinded [...]
Blissco Ships Initial Order to BC Liquor Distribution Branch
08/03/2019
Not for distribution in the U.S. or to U.S. Newswires VANCOUVER, British Columbia, March 08, 2019 (GLOBE NEWSWIRE) -- Blissco Cannabis Corp. ( CSE: BLIS ) ( OTCQB: HSTRF ) ( FRA: GQ4B ), (“Blissco”) or the (“Company”) [...]
BioSig Technologies to Present at the LD Micro Virtual Conference
08/03/2019
Santa Monica, CA, March 08, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed [...]
Strongbridge Biopharma plc Announces New Employment Inducement Awards
08/03/2019
DUBLIN, Ireland and TREVOSE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
08/03/2019
UNITY-CLL DSMB conducted a pre-planned futility analysis of progression-free survival, and determined that the study was not futile and should continue as planned No safety concerns identified by the independent DSMBs [...]
New Trogarzo® Data Presented at Conference on Retroviruses and Opportunistic Infections demonstrates Sustained Viral Suppression at Week 96
08/03/2019
MONTREAL, March 08, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new data, presented today at the 26 th annual Conference on Retroviruses and Opportunistic [...]
De nouvelles données sur Trogarzo(MD), présentées lors de la Conference on Retroviruses and Opportunistic Infections, démontrent une suppression virale continue à la 96e semaine de traitement
08/03/2019
MONTRÉAL, 08 mars 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que de nouvelles données de 96 semaines, présentées lors de la 26 ième édition de la Conference on [...]
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update
08/03/2019
Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development of its rare inherited retinal disease programs Abstract accepted for presentation at European Cystic Fibrosis Society (ECFS [...]
Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019
08/03/2019
BUFFALO, N.Y., March 08, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
PLx Pharma Inc. Reports Fourth Quarter 2018 Results
08/03/2019
– Company Completes Successful $15 Million Financing – HOUSTON, March 08, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused [...]
ChromaDex Brings TRU NIAGEN® to SXSW® 2019
08/03/2019
TRU NIAGEN® milestones to be highlighted at South by Southwest® SXSW® gathering of global professionals LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its [...]
Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
08/03/2019
Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; [...]

Pages